In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China

被引:7
|
作者
Pang, Yu [1 ]
Zheng, Huiwen [2 ]
Tan, Yaoju [3 ]
Song, Yuanyuan [2 ]
Zhao, Yanlin [2 ]
机构
[1] Capital Med Univ, Beijing TB & Thorac Tumor Inst, Beijing Chest Hosp, Natl Clin Lab TB,Beijing Key Lab Drug Resistant T, Beijing, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, Beijing, Peoples R China
[3] Guangzhou Chest Hosp, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China
关键词
nontuberculous mycobacteria; bedaquiline; ECOFF; ATP SYNTHASE INHIBITOR; ANTIMICROBIAL SUSCEPTIBILITY; LUNG-DISEASE; TUBERCULOSIS; RESISTANCE; DRUG; DIAGNOSIS; INFECTIONS; CLOFAZIMINE; MECHANISMS;
D O I
10.1128/AAC.02627-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The main goal of our study was to evaluate the in vitro bedaquiline susceptibility of six prevalent species of pathogenic nontuberculous mycobacteria (NTM) in China. In addition, we investigated the potential molecular mechanisms contributing to bedaquiline resistance in the different NTM species. Among slowly growing mycobacteria (SGM), bedaquiline exhibited the highest activity against Mycobacterium avium; the MIC50 and MIC90 values were 0.03 and 16 mg/liter, respectively. Among rapidly growing mycobacteria (RGM), Mycobacterium abscessus subsp. abscessus (M. abscessus) and Mycobacterium abscessus subsp. massiliense (M. massiliense) seemed more susceptible to bedaquiline than Mycobacterium fortuitum, with MIC50 and MIC90 values of 0.13 and > 16 mg/liter, respectively, for both species. On the basis of bimodal distributions of bedaquiline MICs, we proposed the following epidemiological cutoff (ECOFF) values: 1.0 mg/liter for SGM and 2.0 mg/liter for RGM. Among M. avium, Mycobacterium intracellulare, Mycobacterium kansasii, M. abscessus, M. massiliense, and M. fortuitum isolates, 14 (29.8%), 41 (27.2%), 33 (39.3%), 44 (20.2%), 42 (25.8%), and 7 (31.8%), respectively, were resistant to bedaquiline. No significant differences in the proportions of bedaquiline resistance among these species were observed (P > 0.05). Genetic mutations were observed in 74 isolates (10.8%), with all nucleotide substitutions being synonymous. In conclusion, our data demonstrate that bedaquiline shows moderate in vitro activity against NTM species. Using the proposed ECOFF values, we could distinguish between bedaquiline-resistant and -susceptible strains with the broth dilution method. In addition, no nonsynonymous mutations in the atpE gene that conferred bedaquiline resistance in all six NTM species were identified.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] AGGREGATION OF NONTUBERCULOUS MYCOBACTERIA IN VITRO AND IN SITU
    DePas, W.
    Bergkessel, M.
    Newman, D. K.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S342 - S342
  • [22] In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
    Zhang, Huiyun
    Hua, Wenya
    Lin, Siran
    Zhang, Yu
    Chen, Xinchang
    Wang, Shiyong
    Chen, Jiazhen
    Zhang, Wenhong
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 4845 - 4852
  • [23] In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease
    Kim, Dae Hun
    Kim, Bo-Guen
    Kim, Su-Young
    Huh, Hee Jae
    Lee, Nam Yong
    Koh, Won-Jung
    Kim, Hojoong
    Kwon, O. Jung
    Jhun, Byung Woo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [24] Activities of Linezolid against nontuberculous mycobacteria
    Cavusoglu, Cengiz
    Soyler, Ilknur
    Akinci, Pinar
    NEW MICROBIOLOGICA, 2007, 30 (04): : 411 - 414
  • [25] In vitro activity of bedaquiline against Mycobacterium avium complex
    Litvinov, Vitaly
    Makarova, Marina
    Kudlay, Dmitry
    Nikolenko, Nikolai
    Mikhailova, Julia
    JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 70 (10)
  • [26] In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran
    Heidarieh, Parvin
    Mirsaeidi, Mehdi
    Hashemzadeh, Mohamad
    Feizabadi, Mohamad Mehdi
    Bostanabad, Saeed Zaker
    Nobar, Mostafa Ghalami
    Shahraki, Abodolrazagh Hashemi
    MICROBIAL DRUG RESISTANCE, 2016, 22 (02) : 172 - 178
  • [27] In vitro activity of fidaxomicin against nontuberculosis mycobacteria
    Sun, Qing
    Liao, Xinlei
    Wang, Chenqian
    Jiang, Guanglu
    Yang, Jing
    Zhao, Jianhong
    Huang, Hairong
    Wang, Guirong
    Li, Hao
    JOURNAL OF MEDICAL MICROBIOLOGY, 2022, 71 (06)
  • [28] Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria
    de Almeida, Aryadne L.
    Caleffi-Ferracioli, Katiany R.
    Scodro, Regiane B. de L.
    Baldin, Vanessa P.
    Montaholi, Debora C.
    Spricigo, Luiza F.
    Nakamura-Vasconcelos, Sandra S.
    Hegeto, Laise A.
    Sampiron, Eloisa G.
    Costacurta, Giovana F.
    Yamazaki, Diego A. dos S.
    Gauze, Gisele de F.
    Siqueira, Vera L. D.
    Cardoso, Rosilene F.
    FUTURE MICROBIOLOGY, 2019, 14 (04) : 331 - 344
  • [29] Efflux Pump Inhibitors against Nontuberculous Mycobacteria
    Rindi, Laura
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 13
  • [30] In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical Isolates
    Kim, Dae Hun
    Kim, Su-Young
    Huh, Hee Jae
    Lee, Nam Yong
    Koh, Won-Jung
    Jhun, Byung Woo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (05)